Sun Pharma delivered a strong performance in the December 2025 quarter, supported by steady growth across key markets and improved operating efficiency, leading to healthy expansion in profitability. • Sales: ↑ 13% YoY to ₹15,521 crore (vs ₹13,675 crore in Dec 2024) • EBIDT: ↑ 23% YoY to ₹4,948 crore (vs ₹4,009 crore) • Net Profit: ↑ 19% YoY to ₹3,381 crore (vs ₹2,913 crore) • EPS: ↑ 16% YoY to ₹14.04 (vs ₹12.10) At a price of ₹1,595, market cap ₹3,82,766 crore, and PE 31.5, Sun Pharma continues to command a premium for its strong specialty portfolio and consistent execution. The faster growth in EBIDT over revenue highlights margin expansion and operating leverage, reinforcing its position as a leading pharmaceutical major with sustained earnings visibility.

#PersonalFinance#StockInNews#FundamentalViews#MacroViews#EquityResearch

508 likes·82 comments